44th week of 2014 patent applcation highlights part 56 |
Patent application number | Title | Published |
20140323324 | Method for Enrichment and Separation of Spinal Fluid Glycoprotein, Method for Searching for Marker for Central Nervous System Diseases Which Utilizes the Aforementioned Method, and Marker for Central Nervous System Diseases - The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof. | 2014-10-30 |
20140323325 | Molecular imaging and related methods - The present invention generally relates to imaging single molecules, or one or more collections of single molecules, and methods related to the imaging. In a method aspect, the present invention provides a method of imaging single molecules. The method comprises the steps of: a) exposing a test sample to a probe, wherein the probe comprises a first portion that specifically binds to a target molecule and a second portion that is detectable as the result of one or more chemical groups that interact with light at one or more wavelengths, wherein the probe binds to a target molecule to provide a complex; b) exposing the complex to one or more wavelengths of light that interact with the one or more chemical groups; c) detecting a result from the interacting of one or more wavelengths of light that interact with the one or more chemical groups to provide an image of one or more single molecules. The image possesses a resolution better than 450 nm over a view field area of at least 1×10 | 2014-10-30 |
20140323326 | METHODS FOR THE ELECTROCHEMICAL TREATMENT OF SELF-ASSEMBLED MONOLAYERS - The present invention provides compositions and methods directed to an electrode initialization step for the electrochemical treatment of monolayers used in electrochemical detection of target analytes on the surface of a monolayer. Electrode initialization creates a more stable monolayer, and resolves variability within the electrochemical signal detected on the monolayer. | 2014-10-30 |
20140323327 | ANIMALS, REPERTOIRES & METHODS - The present invention is directed to the concept of sectoring antibody gene segment repertoires in order to enable the development of novel, synthetic antibody chain repertoires not seen in nature. The present invention is also directed to the realisation of the inventors that sectoring can also alter gene segment expression by providing new arrangements of gene segment clusters relative to other gene segments and regulatory elements in transgenic immunoglobulin loci, thereby providing for new synthetic antibody chain sequence repertoires. The invention also relates to gene segment inversion. | 2014-10-30 |
20140323328 | METHOD - The invention provides a method of measuring the affinity of first and second biomolecules in which a first biomolecule is tethered by a first tether portion having a first tether portion length and a second biomolecule is tethered by a second tether portion having a second tether portion length, the method comprising determining binding of adjacent first and second biomolecules to each other, varying at least one of the first and second tether lengths and determining binding of the first and second biomolecules. The invention also provides apparatus suitable for use in the method of the invention. | 2014-10-30 |
20140323329 | Gene Fusion - The disclosure provides gene fusion variants and novel associations with disease states, as well as kits, probes, and methods of using the same. | 2014-10-30 |
20140323330 | MICROARRAY COMPOSITIONS AND METHODS OF THEIR USE - Microarray compositions suitable for analysis by one or several spectrographic methods are disclosed. In an embodiment, a microarray composition includes a three-dimensional solid support and a plurality of reactive microbeads positioned on the solid support in spatially distinct and addressable locations. | 2014-10-30 |
20140323331 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ACNE VULGARIS - Described herein are methods, systems, platforms, and kits for the characterization, assessment, diagnosis and treatment of acne vulgaris. Among the methods provided are methods of identifying a gene expression profile for acne vulgaris and biomarkers for monitoring treatment. Also provided are methods, systems, platforms, and kits for monitoring efficacy of a treatment and methods for selecting a treatment regimen. | 2014-10-30 |
20140323332 | MULTIPLEX HEPATITIS B ASSAY - Provided herein are multiplex assays for determining whether an individual is or has been infected with Hepatitis B virus, and the stage of infection or resolution. In addition, the multiplex system can discriminate between vaccinated subjects and subjects susceptible to Hepatitis B infection. | 2014-10-30 |
20140323333 | FLOW CYTOMETRY ASSAY METHODS - This document provides methods and materials involved in performing flow cytometry assay methods. For example, flow cytometry assay methods and kits are provided. | 2014-10-30 |
20140323334 | Interference Control Panel for Evaluation of Analytical Assays For Samples Derived from Blood - The invention relates to quality control of analytical assays, particularly NAT assays of blood samples containing nucleic acids. A control panel containing quantified amounts of substances known to interfere with an analytical assay is used and compared with a reference sample in the analytical assay. A comparison of the assay results interference panel validates the assay and can serve as a periodic quality control check for the analytical assay as well as related methods and protocols. The use of the control panel of the invention can also determine whether interfering substances are present and establish under what conditions the analytical assay reliable. | 2014-10-30 |
20140323335 | Methods of Novel Therapeutic Candidate Identification Through Gene Expression Analysis in Vascular-Related Diseases - The present invention discloses multiple treatment regimens for vascular-related diseases and disorders. The present invention provides for methods of treating vascular-related disorders based on gene expression studies from samples collected from individuals having symptoms of vascular-related disorders. Additionally, methods are disclosed involving diagnostic techniques to focus treatment regimens. Finally, methods of treating vascular-related disorder involving targeting microRNAs are also disclosed. | 2014-10-30 |
20140323336 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE - A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels. | 2014-10-30 |
20140323337 | MONOLITHIC DEVICE COMBINING CMOS WITH MAGNETORESISTIVE SENSORS - A monolithic device comprises a substrate. An array of sensing elements is coupled to the substrate, and each sensing element includes a magnetoresistive sensor. An analog electric drive generator is coupled to the substrate, and the electric drive generator produces a sensor-biasing signal that biases the magnetoresistive sensors of the array. An analog multiplexer is coupled to the substrate, and outputs of the array are coupled to inputs of the multiplexer. An analog signal conditioning circuit is coupled to the substrate, wherein at least one output of the multiplexer is coupled to at least one input of the signal conditioning circuit. The monolithic device is fabricated using both complementary metal-oxide semiconductor (i.e., CMOS) technology and thin film technology. For example, the electric drive generator, the multiplexer, and the signal conditioning circuit may be fabricated with CMOS technology, while the magnetoresistive sensors of the array are fabricated with thin film technology. | 2014-10-30 |
20140323338 | BIOMARKERS FOR PREDICTION, DIAGNOSIS, AND MONITORING OF ALZHEIMER'S DISEASE - A method for the risk detection, early diagnosis, prognosis, and monitoring of Alzheimer's disease in an individual by measuring the amount of specific biomarkers present in a bodily fluid and comparing them to a reference level of biomarkers in a sample from a healthy person, a person previously diagnosed with Alzheimer's disease, or an earlier sample from the individual of interest. | 2014-10-30 |
20140323339 | METHODS TO ASSAY KINASE ACTIVITY - Methods and kits for enzymes involved in post-translational modifications are provided. The methods employ elemental analysis, including ICP-MS. The methods allow for the convenient and accurate analysis of post-translation modifications of substrates by enzymes involved in post-translational modifications, including kinase and phosphatase enyzmes | 2014-10-30 |
20140323340 | SENSITIVE AND RAPID DETERMINATION OF ANTIMICROBIAL SUSCEPTIBILITY - The present invention relates to moving microorganisms to a surface, where they are grown in the presence and absence of antimicrobials, and by monitoring the growth of the microorganisms over time in the two conditions, their susceptibility to the antimicrobials can be determined. The microorganisms can be moved to the surface through electrophoresis, centrifugation or filtration. When the movement involves electrophoresis, the presence of oxidizing and reducing reagents lowers the voltage at which electrophoretic force can be generated and allows a broader range of means by which the target can be detected. Monitoring can comprise optical detection, and most conveniently includes the detection of individual microorganisms. The microorganisms can be stained in order to give information about their response to antimicrobials. | 2014-10-30 |
20140323341 | SYSTEMS AND METHODS FOR ASSESSMENT OF BIOSIMILARITY - A method of determining biosimilarity of a sample composition to a reference composition, including: exposing a test cell system to a sample composition so that the test cell system responds to the sample composition by change in transcription factor activity in the test cell system; generating from the test cell system response an output correlative to the change of transcription factor activity in the test cell system; and determining from comparison of said output with a transcription factor activity reference standard for the reference composition, the biosimilarity of the sample composition to the reference composition. Computer systems and kits for carrying out the determination of biosimilarity of compositions are also described, in which biosimilarity of compositions ranging from simple molecules to complex mixtures can be readily and accurately determined by transcription factor activity analysis. | 2014-10-30 |
20140323342 | Methods and Compositions for the Treatment and Diagnosis of Bladder Cancer - The invention provides methods, compositions and kits for the detection and treatment of bladder cancer. | 2014-10-30 |
20140323343 | BIOMARKERS FOR ASSESSING IDIOPATHIC PULMONARY FIBROSIS - Disclosed are methods are kits for evaluating predicting whether an individual IPF has slowly or rapidly progressive IPF. | 2014-10-30 |
20140323344 | Differential Identification of Pancreatic Cysts - More than 2% of adults harbor a pancreatic cyst, a subset of which progress to invasive lesions with lethal consequences. To assess the genomic landscapes of neoplastic cysts of the pancreas, we determined the exomic sequences of DNA from the neoplastic epithelium of eight surgically resected cysts of each of the major neoplastic cyst types: serous cystadenomas (SCAs), intraductal papillary mucinous neoplasms (IPMNs), mucinous cystic neoplasms (MCNs) and solid pseudo-papillary neoplasms (SPNs). SPNs are low-grade malignancies, and IPMNs and MCNs, but not SCAs, have the capacity to progress to cancer. We found that SCAs, IPMNs, MCNs, and SPNs contained 10=4.6, 27=12, 16=7.6, and 2.9=2.1 somatic mutations per tumor, respectively. Among the mutations identified, E3 ubiquitin ligase components were of particular note. Four of the eight SCAs contained mutations of VHL, a key component of the VHL ubiquitin ligase complex that has previously been associated both with renal cell carcinomas, SCAs, and other neoplasms. Six of the eight IPMNs and three of the eight MCNs harbored mutations of RNF43, a gene coding for a protein with intrinsic E3 ubiquitin ligase activity that has not previously been found to be genetically altered in any human cancer. The preponderance of inactivating mutations in RNF43 unequivocally establish it as a suppressor of both IPMNs and MCNs. SPNs contained remarkably few genetic alterations, but always contained mutations of CTNNB1, previously demonstrated to inhibit degradation of the encoded protein (β-catenin) by E3 ubiquitin ligases. These results highlight the essential role of ubiquitin ligases in these neoplasms and have important implications for the diagnosis and treatment of patients with cystic tumors. | 2014-10-30 |
20140323345 | NOVEL MARKERS OF PAPILLARY AND RETICULAR FIBROBLASTS AND USES THEREOF - An in vitro method for screening for candidate compounds for preventing and/or attenuating skin ageing, and/or hydrating skin, includes: a) contacting a test compound with a sample of papillary fibroblasts; b) measuring the expression of a gene selected from PDPN, CCRL1 and NTN1, in the papillary fibroblasts; and c) selecting compounds for which an activation of at least 1.5 fold of the expression of at least one of the genes is measured in the treated papillary fibroblasts compared with untreated papillary fibroblasts. Another in vitro method includes: a) contacting a test compound with a sample of reticular fibroblasts; b) measuring the expression of a gene selected from MGP, PPP1R14A and TGM2, in the reticular fibroblasts; and c) selecting compounds for which an activation of at most 1.0 fold of the expression of at least one of the genes is measured in the treated reticular fibroblasts compared with untreated reticular fibroblasts. | 2014-10-30 |
20140323346 | BINDING AGENT - The present disclosure generally relates to protein binding agents, such as protein kinase binding agents of general Formula (I). The protein binding agents may be provided attached to a solid support and may be used, for example, to detect the presence of a broad range of proteins in a sample. Methods of synthesizing the protein binding agents, and kits comprising the protein binding agents, are also disclosed. | 2014-10-30 |
20140323347 | POINT OF CARE IMMUNIZATION TESTING SYSTEM - A point of care immunization system based upon microfluidics and micro-titration technologies to rapidly test a patient in order to ascertain an immunization profile so that vaccinations can be administered to address identified gaps. A point of care system comprised of uniquely shaped and color distinguishing sample and test cartridges, with said test cartridges configured to meet healthcare requirements of national governing bodies. A point of care system including an easy access vaccine storage device with indicators to provide data on viability of stored vaccines. | 2014-10-30 |
20140323348 | EXPRESSION OF G-PROTEIN COUPLED RECEPTORS (GPCRs) - Disclosed are methods of promoting and/or enhancing G-Protein Coupled Receptor (GPCR) localization to the cell membrane and/or cell surface; methods of promoting and/or enhancing GPCR functional expression; and methods and assays for screening or identifying ligands (e.g., agonists or antagonists) that bind GPCRs. Also provided are vectors, recombinant cells, and stable cell lines for use in the methods and assays. | 2014-10-30 |
20140323349 | COMPOSITIONS AND METHODS FOR MONITORING AND DETECTING CANCEROUS CONDITIONS - A method for monitoring or detecting a prostate condition in a subject comprises determining Engrailed-2 (EN2) gene, Paired Box 2 (PAX2) gene, and/or β defensin-1 (DEFB1) gene expression levels in a biological sample from the subject. The expression levels of EN2, PAX2 and/or DEFB1 gene are correlated with cancerous, pre-cancerous, or non-cancerous prostate conditions. | 2014-10-30 |
20140323350 | ELECTRONIC LATERAL FLOW TEST ARRANGEMENT AND METHOD - A lateral test flow arrangement for a test molecule is disclosed, comprising: a test strip for transporting an analyte away from a sampling region and towards an absorbing region, the test strip having therein and remote from the sampling region, a test region for functionalization with a molecule which binds to the test molecule or to a conjugate of the test molecule; a sensing test capacitor having electrodes extending across the test strip at least partially aligned with the test region and being physically isolated therefrom; a reference test capacitor having electrodes extending across the test strip and being physically isolated therefrom; and an electronic circuit configured to measure a time-dependant capacitance difference between the sensing test capacitor and the reference test capacitor. A method for carrying out that lateral flow tests is also disclosed, as are test systems and in particular pregnancy test systems | 2014-10-30 |
20140323351 | SINGLE CELL ARRAY MICROCHIP AND FABRICATION, ELECTRICAL MEASUREMENT AND ELECTROPORATION METHOD THEREOF - The present invention relates to single cell array micro-chips and fabrication, electrical measurement and electroporation method thereof. The single cell array microchip comprises a substrate ( | 2014-10-30 |
20140323352 | Means and Methods for Diagnosing Pancreatic Cancer in a Subject - The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing pancreatic cancer in a subject, a method for identifying whether a subject is in need for a therapy of pancreatic cancer or a method for determining whether a pancreatic cancer therapy is successful. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices. | 2014-10-30 |
20140323353 | CELL-BASED ARRAYS, METHODS OF MAKING, AND METHODS OF USING - Embodiments of the present disclosure provide for arrays, systems, and methods analyzing cells, methods of making arrays, and the like. | 2014-10-30 |
20140323354 | Chemically Modified Ligase Cofactors, Donors and Acceptors - Provided herein are methods for ligation of polynucleotides containing modified ligation components, particularly modified ligase cofactors, modified acceptors and modified donors. The methods readily applied to ligation-based assays for detection of a nucleic acid sequence where the use of the modified cofactor improves discrimination between matched and mismatched templates. Furthermore, the use of the modified ligation components reduces or eliminates the ligation in the absence of nucleic acid template. In addition, methods are applied to the preparation of nucleic acid libraries using modified acceptor probes and modified donor probes that reduce or eliminate probe dimerization during the ligation process. | 2014-10-30 |
20140323356 | GLYCOSIDASE ENZYMES - A thermostable glycosidase enzymes derived from various | 2014-10-30 |
20140323357 | MICROFLUIDIC CARTRIDGE AND METHOD OF MAKING SAME - The present technology provides for a microfluidic substrate configured to carry out PCR on a number of polynucleotide-containing samples in parallel. The substrate can be a single-layer substrate in a microfluidic cartridge. Also provided are a method of making a microfluidic cartridge comprising such a substrate. Still further disclosed are a microfluidic valve suitable for use in isolating a PCR chamber in a microfluidic substrate, and a method of making such a valve. | 2014-10-30 |
20140323358 | Vacuum Assist for a Microplate - A vacuum assist apparatus can comprise a microplate. The microplate can comprise a first surface and an opposing second surface. A plurality of wells can be formed in the first surface of the microplate. Each of the plurality of wells can be sized to receive an assay therein. A support base can comprise a fluid passage. The microplate can be positioned adjacent and in contact with the support base. A pressure device, in fluid communication with the fluid passage, can exert a vacuum within the fluid passage to actively retain the microplate in the contact with the support base. | 2014-10-30 |
20140323359 | METHODS OF TREATING A WELL WITH A FLUORINATED LUBRICANT OR CORROSION INHIBITOR - A treatment fluid comprises: a base fluid; and at least one additive, wherein the additive: (i) comprises a fluorinated compound; and (ii) is a lubricant that is surface active. The additive can reduce the coefficient of friction between two or more surfaces. The surfaces can be the surface of a wellbore component. The additive can also be a corrosion inhibitor. A method of treating a portion of a well comprises: forming the treatment fluid; and introducing the treatment fluid into the well. | 2014-10-30 |
20140323360 | NOVEL STRONTIUM CARBONATE BRIDGING MATERIALS AND METHODS FOR MAKING AND USING SAME - Drilling fluids were developed including a base fluid, a weighting agent and/or a bridging agent, and a thickening agent, where the weighting agent and/or the bridging agent includes a particulate strontium carbonate having a desired distribution, for weighting agents, the distribution includes particles between 2μ and 5000μ and for bridging agents, the distribution is constructed from particles having specific sizes. Methods making and using the drilling fluids were also discovered. | 2014-10-30 |
20140323361 | TREATMENT OF SUBTERRANEAN FORMATIONS USING A COMPOSITION INCLUDING A LINEAR TRIBLOCK COPOLYMER AND INORGANIC PARTICLES - The present invention relates to treatment of subterranean formations using compositions that experience an increase in viscosity as a result of the application of heat or shear. In various embodiments, the present invention provides a method of treating a subterranean formation. The method can include obtaining or providing a composition including a linear triblock copolymer and inorganic particles. The method can include at least one of shearing and heating the composition, to increase the viscosity thereof. The method can also include contacting the composition with a subterranean material downhole. | 2014-10-30 |
20140323362 | DEFOAMER FORMULATION AND METHODS FOR MAKING AND USING SAME - Defoamer compositions are disclosed and methods for making and using same, where the defoamer has universal applicability at low concentrations. The defoamer compositions include between 40 vol. % and about 80 vol. % distilled water (other waters may be used instead), 10 vol. % and about 30 vol. % of silicon anti-foam agent and between about 10 vol. % and about 30 vol. % of active silicon anti-foam agent. The defoamer compositions are used in amount of less than or equal to 200 ppm in all foamed downhole fluid systems. | 2014-10-30 |
20140323363 | NANOTRACERS FOR LABELING OIL FIELD INJECTION WATERS - This invention relates to the development of nanoparticles, which can be used as tracers, in order to track the movement of fluids injected into an oil reservoir. The injected fluids diffuse through a solid geological medium which constitutes the oil reservoir, thus making it possible to study this latter by following the path of the injected fluids. The objective is in particular to monitor the flows between the injection well(s) and the production well(s) and/or to evaluate the volumes of oil in reserve and water in the reservoir and ultimately to optimize oil exploration and exploitation. | 2014-10-30 |
20140323364 | High Strength Low Density Synthetic Proppants for Hydraulically Fracturing and Recovering Hydrocarbons - There is provided synthetic proppants, and in particular polysilocarb derived ceramic proppants. There is further provided hydraulic fracturing treatments utilizing these proppants, and methods of enhance hydrocarbon recovery. | 2014-10-30 |
20140323365 | Polylactide Fibers - Polylactide fibers are made from a blend of polylactides. One of the polylactides has a ratio of R-lactic and S-lactic units from 8:92 to 92:8. The second polylactide has a ratio of the R-lactic and S-lactic units of >97:3 or <3:97. The ratio of the R-lactic units to S-lactic units in the blend is from 7:93 to 25:75 or from 75:25 to 93:7. The polylactide fiber contains at least 5 Joules of polylactide crystallites per gram of polylactide resin in the fiber. | 2014-10-30 |
20140323366 | DRAG-REDUCING COPOLYMER COMPOSITIONS - A method of preparing and using a drag-reducing composition in a well treatment operation includes the step of preparing the drag-reducing composition by mixing a polymer emulsion that includes a first surfactant and a first solvent, with a second surfactant and a second solvent. The method continues with the step of combining the drag-reducing composition with an aqueous treatment fluid. The method further includes the step of injecting the drag-reducing composition and aqueous treatment fluid into a subterranean formation, a pipeline or a gathering line. | 2014-10-30 |
20140323367 | ELEMENT COMPRISING AT LEAST ONE SLIDING SURFACE HAVING A COATING FOR USE IN AN INTERNAL COMBUSTION ENGINE OR A COMPRESSOR - An element with at least one slide surface with a coating for use on an internal combustion engine may include a base of a metallic alloy and at least one inner surface provided with a hard ceramic coating generated by physical vapor deposition. The element may include a porosity with a rate lower than 2 percent by volume, a Vickers hardness ranging from 1500 to 3000HV, and a compressive inner tension lower than 500 MPa. | 2014-10-30 |
20140323368 | SLIDING COMPONENT FOR USE IN AN INTERNAL COMBUSTION ENGINE - The present invention relates to a sliding component for use in internal combustion engines, provided with a ferrous base ( | 2014-10-30 |
20140323369 | USE OF AMINES IN HEAVY OIL TRANSPORT - Provided herein are, inter alia, heavy crude oil emulsion compositions and methods of making the same. The compositions and methods provided herein are particularly useful for the transport of heavy crude oils. | 2014-10-30 |
20140323370 | BRAKE FLUID COMPOSITION COMPRISING TARTARIC ACID AND IMIDAZOLE - The present invention relates to a brake fluid composition comprising (a) a glycol compound and boron-containing compound mixture as solvents, (b) corrosion inhibitior, (c) and tartatric acid, imidazole or a mixture of tartaric acid and imidazole as antioxidants. Provided is a brake fluid composition having improved capabilities for inhibiting thermal oxidation, metallic and high-temperature corrosion. The brake fluid composition according to the present invention significantly improves long-term durability by reducing metal dot corrosion and preventing boronic acid precipitation on a test piece, while having a superior thermal oxidation inhibition capability, and has superior capabilities for inhibiting high-temperature oxidation and corrosion while having negligible effects on the equilibrium reflux boiling point and the wet equilibrium reflux boiling point. | 2014-10-30 |
20140323371 | WORKING FLUID - A working fluid whose base material is a glycol, characterized in that such working fluid contains a modified silicone oil. | 2014-10-30 |
20140323372 | Low Ash Lubricants with Improved Seal and Corrosion Performance - A lubricant composition of (a) an oil of lubricating viscosity; (b) a dispersant comprising the condensation product of a carboxylic functionalized polymer with an aromatic amine having at least 3 aromatic rings and at least one primary or secondary amino group; and (c) an overbased metal detergent comprising an oil-soluble neutral metal salt component and a metal carbonate component, provides good seal and corrosion performance. The total amount of neutral metal salt component in the lubricant composition is at least about 0.75 percent by weight and the sulfated ash level of the lubricant composition is less than about 1.1 percent. | 2014-10-30 |
20140323373 | NOVEL SULPHUR-BRIDGED COMPOUNDS, USE THEREOF AND PROCESS FOR PRODUCTION THEREOF - The present invention relates to novel sulphur-bridged compounds, in which within the molecule there is at least one fatty acid bonded by way of at least one sulphur bridge to at least one polyalkylene glycol ester, the reaction product of a fatty acid with a polyalkylene glycol, and these have from 8 to 29% by weight sulphur content, to use of these as sulphur carrier and lubricant additive and to production of the said compounds. | 2014-10-30 |
20140323374 | Lubricating Shaving Aid Member - A shaving aid member comprising a lubricating material, the lubricating material comprising a water soluble polymer having an average molecular weight of at least 5,000, and a copolymer of polyethylene oxide and polypropylene oxide. | 2014-10-30 |
20140323375 | COMBINATION OF AN AMINO ALCOHOL, A FRAGRANCE AND A SILICIC ACID ESTER, AND THE USE OF SAME AS A PRO-FRAGRANCE - The invention relates to a composition of (a) a selected amino alcohol compound of general formula (I), (b) a scent aldehyde and/or scent ketone, and (c) a selected silicic acid ester, to the use of same as a pro-scent, as well as to washing and cleaning agents, fabric softeners and cosmetics which contain these. The invention also relates to a method for prolonging the perception of scent in such agents, and to a method for removing malodors by applying said composition. | 2014-10-30 |
20140323376 | MICROCAPSULES AND USES THEREOF - The present invention relates to core-shell microcapsules comprising photolabile 2-oxoacetate pro-fragrance molecules capable of liberating an active molecule such as, for example, an aldehyde or ketone upon exposure to light. The present invention concerns also the use of said microcapsules in perfumery as well as the perfuming compositions or perfumed articles comprising the invention's microcapsules to provide a prolonged release of fragrant aldehydes and/or ketones. | 2014-10-30 |
20140323377 | UNDERCOAT LAYER AND IMAGING MEMBERS COMPRISING SAME - Disclosed are undercoat layers comprising a metal oxide, a polymer, and a citrate of Formula (I): | 2014-10-30 |
20140323378 | Coating Systems - The invention relates to a coating system, in particular a coating system containing an organometallic layer which allows the selective removal of post coating layers from substrates without detrimental impact to their “in-service” performance. The organometallic layer comprises (a) an organic polymer containing multi-chelating functionalities; and (b) a metallic agent which forms an organo metallic complex with the organic polymer containing multi-chelating functionalities and is located between an optionally coated substrate and at least one post coating layer of a coating system. | 2014-10-30 |
20140323379 | WASHING AND CLEANING AGENTS CONTAINING GLYCERIN ESTERS - It has been discovered according to the present invention that glycerol esters effectively prevent or at least decrease the discoloration of plastic dishes in the context of automatic dishwashing. | 2014-10-30 |
20140323380 | CLEANING AND DISINFECTING LIQUID HAND DISHWASHING DETERGENT COMPOSITIONS - The invention relates to a liquid cleaning and disinfecting hand dishwashing detergent composition comprising at least one surfactant selected from the group consisting of anionic, nonionic, cationic, zwitterionic, amphoteric surfactants, and mixtures thereof, at least one organic solvent and/or at least one hydrotrope, and a single antibacterial active and/or at least one sequestering agent. The cleaning and disinfecting hand dishwashing detergent composition eliminates 99.999% of | 2014-10-30 |
20140323381 | ACYL HYDRAZONES AS BLEACH-BOOSTING ACTIVE SUBSTANCES - The aim of the invention is to improve the cleaning performance of washing and cleaning agents against stains from polysaccharide-containing food residue. This is substantially achieved by incorporating a combination of peroxide bleaching agents with specific acyl hydrazones. | 2014-10-30 |
20140323382 | Detergent Compositions - The present invention relates a method of obtaining a detergent composition comprising introducing (a) a lipase variant of a parent lipase which variant has at least 60% sequence identity with SEQ ID NO: 2, a substitution at a position corresponding to D254 of the mature polypeptide of SEQ ID NO: 2 and has lipase activity and (b) an anionic surfactant, wherein said composition has increased stability in comparison with a corresponding composition comprising the parent lipase. | 2014-10-30 |
20140323383 | POUCH COMPRISING A LIQUID DETERGENT COMPOSITION - A pouch comprising a water-soluble film and a liquid detergent composition contained within the water-soluble film. The liquid detergent composition comprising: a) an alkanolamine; b) a sulfite; c) a perfume oil comprising aldehyde or ketone; and d) a sulfur-containing pro-perfume compound, delivers improved stability and perfume longevity. | 2014-10-30 |
20140323384 | Composition - A particulate material comprising a bleach catalyst wherein the particles of the bleach catalyst have a coating and the weight ratio of the coating to the bleach catalyst is in the range of from 10-60 wt %. The particulate material exhibits good stability. | 2014-10-30 |
20140323385 | FAST DISSOLVING SOLID DETERGENT - A solid block or unit dosed detergent composition as described which can be utilized in a variety of applications for cleaning surfaces and objects, removing suspending soils, and rinsing easily. The detergent composition, when exposed to an aqueous solution such as water, dissolves quickly and completely to create the use solution. | 2014-10-30 |
20140323386 | COMPOSITION FOR CLEANSING AGENT AND CLEANSING AGENT - The present invention relates to a composition for a cleansing agent comprising a component (A) in the form of an ionic surfactant and a component (B) in the form of one or more types of compounds selected from the group consisting of a hydroxystearic acid polymer and an esterification reaction product of a hydroxystearic acid polymer. According to the present invention, a composition for a cleansing agent can be provided that has favorable foaming power and foam quality, is easily rinsed during cleansing, is free of stickiness after cleansing and allows the obtaining of a moist feeling. | 2014-10-30 |
20140323387 | 5,5-Dimethyl-2-propyl-hexahydro-2,4a-methano-naphthalen-1-one as a fragrance agent - The invention relates to a compound of general formula (I) shown hereafter: | 2014-10-30 |
20140323388 | COMPOSITIONS COMPRISING A FUNCTIONAL PERFUME COMPONENT MIXTURE - Compositions having a mixture of functional perfume components are provided. In one embodiment, the functional perfume components comprise iso-nonyl acetate, dihydro myrcenol, linalool, and benzyl acetate. In one embodiment, the functional perfume component may be present in an amount from about 75% to about 100%, by weight of said mixture, wherein said composition is substantially free of a VOC. | 2014-10-30 |
20140323389 | METHODS FOR PREVENTING OR TREATING DISORDERS BY INCREASING BIOAVAILABILITY OF IRON AND RELATED PHARMACEUTICAL FORMULATION - The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition to a subject in need thereof, which composition contains a lipocalin mutein or a fragment or a variant thereof capable of increasing the bioavailability of iron in the subject. | 2014-10-30 |
20140323390 | COMPOUNDS AND COMPOSITIONS AS TLR2 AGONISTS - The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine. | 2014-10-30 |
20140323391 | BIOMARKERS FOR THE MOLECULAR CLASSIFICATION OF BACTERIAL INFECTION - Disclosed herein are biomarkers useful for identifying and/or classifying bacterial infections in a subject. | 2014-10-30 |
20140323392 | METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRY - Disclosed herein are compositions and methods for inhibiting viral entry. | 2014-10-30 |
20140323393 | Uses Of Peptides to Treat Brain Injury and Disease - A method of treating loss of brain function in a patient comprising the steps of preparing a composition comprising a D peptide and a pharmaceutically acceptable carrier. The D peptide has the general structure: A-B-C-D-E-F-G-H in which
| 2014-10-30 |
20140323394 | TRIPEPTIDE KDPT FOR ANTIAPOPTOTIC TREATMENT - The present invention is related to the tripeptide (I)Lys-(d)Pro-(I)Thr (KdPT) or pharmaceutically acceptable salts thereof for therapeutic, prophylactic therapeutic or cosmetic treatment of a disease with increased apoptosis, wherein the treatment has an anti-apoptotic effect. The present invention is also related to the use of KdPT or pharmaceutically acceptable salts thereof for the manufacture of a pharmaceutical or cosmetic composition for an anti-apoptotic treatment of disorders that are related with increased apoptosis. | 2014-10-30 |
20140323395 | Methods for Treating HCV - The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir). | 2014-10-30 |
20140323396 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 2014-10-30 |
20140323397 | TREATMENTS FOR GASTROINTESTINAL DISORDERS - The present invention provides new uroguanylin derivatives that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms. | 2014-10-30 |
20140323398 | ULTRA-CONCENTRATED RAPID-ACTING INSULIN ANALOGUE FORMULATIONS - A pharmaceutical formulation comprises insulin having a variant insulin B-chain polypeptide containing an ortho-monofluoro-Phenylalanine substitution at position B24 in combination with a substitution of an amino acid containing an acidic side chain at position B10, allowing the insulin to be present at a concentration of between 0.6 mM and 3.0 mM. The formulation may optionally be devoid of zinc. Amino-acid substitutions at one or more of positions B3, B28, and B29 may additionally be present. The variant B-chain polypeptide may be a portion of a proinsulin analogue or single-chain insulin analogue. The insulin analogue may be an analogue of a mammalian insulin, such as human insulin. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to the patient. | 2014-10-30 |
20140323399 | COMPOSITIONS AND METHODS FOR INCREASING INSULIN SENSITIVITY - Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin. | 2014-10-30 |
20140323400 | USE OF FIBROMODULIN AND LUMICAN FOR INCREASING MUSCLE MASS - The invention relates to the use of fibromodulin and lumican, particularly active fragments thereof, to increase muscle mass, especially in the treatment of muscular dystrophies. | 2014-10-30 |
20140323401 | TISSUE PROTECTIVE PEPTIDES AND USES THEREOF - The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor. The invention is further directed to the consensus sequences for use in engineering a synthetic tissue protective peptide. These tissue protective peptides also include fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO. The invention further encompasses methods for treating or preventing a disease or disorder using tissue protective peptides of the current invention. The invention also encompasses methods for enhancing excitable tissue function using tissue protective peptides of the current invention. | 2014-10-30 |
20140323402 | Protein Carrier-Linked Prodrugs - The present invention relates to water-soluble protein carrier-linked prodrugs wherein the protein carrier comprises an amino acid sequence consisting of at least 100 amino acid residues forming random coil conformation and comprising alanine, serine and proline residues. It further relates to pharmaceutical compositions comprising said water-soluble protein carrier-linked prodrugs, their use as a medicament as well as methods of treatment and administration. | 2014-10-30 |
20140323403 | HEMOGLOBIN COMPOSITIONS AND METHODS OF USE - A modified hemoglobin oxygen transport agent useful in the treatment of hypoxia and related conditions is disclosed. The composition consists primarily of carbohydrate shielded hemoglobin or a hybrid hemoglobin molecule to deliver oxygen in hypoxia stage. The carbohydrate shielded hemoglobin therapy is based on oxidation physiology, which is believed to play key roles in ischemia, anemia and other conditions related to hypoxia. | 2014-10-30 |
20140323404 | ANTICOAGULANT POLYPEPTIDE AND APPLICATIONS THEREOF - Disclosed is an anticoagulant polypeptide and applications thereof. The anticoagulant polypeptide comprises a polypeptide formed by an amino acid sequence as represented in Seq. ID No. 1; or comprises a derived polypeptide that selectively inhibits coagulation factor XIa and is formed by an amino acid sequence, as represented in Seq. ID No. 1, that has undergone one or multiple amino acid residue substitutions, deletions, or insertions. The anticoagulant polypeptide is a selective inhibitor for coagulation factor XIa, has anticoagulant activity and small side-effect, and can be used in preparing medicines for the prevention and treatment of thrombotic diseases. | 2014-10-30 |
20140323405 | ALPHA-1-ANTITRYPSIN COMPOSITIONS - A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitant. Separation of the solid adsorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described. | 2014-10-30 |
20140323406 | METHOD AND COMPOSITIONS FOR TREATING STROKE WITH FEVER - The invention provides methods of treating stroke and related conditions exacerbated by fever and/or hyperglycemi by administering peptides or peptidomimetics that inhibit binding of NMDAR 2B to PSD-95 to a patient. | 2014-10-30 |
20140323407 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF - In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. | 2014-10-30 |
20140323408 | METHOD OF INHIBITING DOPAMINERGIC CELL DEATH - Soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications for reducing dopaminergic cell death. | 2014-10-30 |
20140323409 | APOTRANSFERRIN FOR THE TREATMENT OF BRAIN STROKE - The present invention relates to the use of apotransferrin for the preparation of a medicament for the treatment of brain stroke. Particularly the invention relates to the use of apotransferrin for the preparation of a medicament for the treatment of brain strokes wherein the drug prepared with apotransferrin is for administration by vascular route, preferably intravenous or intraarterial. | 2014-10-30 |
20140323410 | USE OF HDL-RELATED MOLECULES TO TREAT AND PREVENT PROINFLAMMATORY CONDITIONS - Molecules and compositions are described for use in the treatment and prevention of pro-inflammatory conditions. HDL-related molecules, including ApoA-I, bovine HDL and HDL mimetics, in particular, are demonstrated to prevent UV-induced cell death and oxidative stress in skin cells and to inhibit tumor growth and development in a variety of cancers. HDL-related molecules can be used as an oral supplement and in other compositions to prevent or treat pro-inflammatory skin conditions and systemic proinflammatory conditions, including Alzheimer's disease and various cancers. | 2014-10-30 |
20140323411 | Method for De-Differentiating A Cell - The invention relates to a method for de-differentiating a cell, i.e. the induction of a pluripotent phenotype. In vivo de-differentiation is carried out using defined factors such as transcription factors, miRNA, DNA, or proteins. This leads to the formation of pluripotent cells, without teratoma formation. Defined factors may be administered to cells such as liver or muscle cells and are useful in therapy. | 2014-10-30 |
20140323412 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE - Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof. | 2014-10-30 |
20140323413 | METHODS OF DIAGNOSING AND TREATING VASCULAR ASSOCIATED MACULOPATHY AND SYMPTOMS THEREOF - Disclosed herein are methods and compositions for the diagnosis and treatment of Vascular Associated Maculopathy, or a symptom thereof, in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of one or more symptoms associated with Vascular Associated Maculopathy Disclosed in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of severe maculopathy or last stage maculopathy in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of resolving aberrant choriocapillaris lobules in a subject. | 2014-10-30 |
20140323414 | INOTROPIC COMPOUNDS - The present invention provides the use of a compound which activates at least one of the sodium channels: NAV 1.1, NAV 1.3, NAV 1.6 or a combination of two or more of such sodium channels, in the preparation of a medicament for increasing cardiac output. Moreover, the aim of the invention, is utilizing this compound for increasing cardiac output without affecting cardiac rhythm or without inducing cardiac rhythm disturbance. | 2014-10-30 |
20140323415 | ORGANIC COMPOUNDS - A pharmaceutical composition comprises octreotide acetate microparticles of linear poly(lactide-co-glycolide) polymer wherein the polymer contains less than 1% silicone oil or heptane. | 2014-10-30 |
20140323416 | 5-METHYLDIHYDROMORPHONE COMPOUNDS FOR TREATMENT OF PAIN - The aspects of the present disclosure are directed to novel compounds, formulations containing said compounds or pharmaceutically acceptable salts thereof which are suitable for administration to a patient. In particular, to 5-methyldihydromorphone prodrug compounds described in general Formula I and II and the use of the compounds for treating pain associated with a variety of chronic human disorders including for example neuropathic pain and pain associated with cancer, surgeries or injuries. | 2014-10-30 |
20140323417 | CRYSTALLINE DAPAGLIFLOZIN HYDRATE - A crystalline dapagliflozin hydrate and a process for obtaining the same is described. | 2014-10-30 |
20140323418 | SELECTIVE KINASE INHIBITORS - Provided are pyrimidine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity. | 2014-10-30 |
20140323419 | HIGH EFFICACY COMBINATION THERAPY FOR HELICOBACTER PYLORI ERADICATION AND PACKAGING FOR THE DISTRIBUTION AND USE THEREOF - The invention teaches a method for treatment of | 2014-10-30 |
20140323421 | Combination Therapy for Treating Cancer - The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer. | 2014-10-30 |
20140323422 | Anionic Conjugates of Glycosylated Bacterial Metabolite - The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates to processes for the preparation of the conjugates. Such conjugates are useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory (including allergic) diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites. | 2014-10-30 |
20140323423 | BIOSYNCHRONOUS TRANSDERMAL DRUG DELIVERY FOR LONGEVITY, ANTI-AGING, FATIGUE MANAGEMENT, OBESITY, WEIGHT LOSS, WEIGHT MANAGEMENT, DELIVERY OF NUTRACEUTICALS, AND THE TREATMENT OF HYPERGLYCEMIA, ALZHEIMER'S DISEASE, SLEEP DISORDERS... - Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, plant extracts, botanicals, nutraceuticals, cosmeceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor. The system can utilize a pump, pressurized reservoir, a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with porous membranes or micro-fabricated structures. | 2014-10-30 |
20140323424 | METHODS FOR ASSESSMENT AND TREATMENT OF MOOD DISORDERS VIA SINGLE NUCLEOTIDE POLYMORPHISMS ANALYSIS - Described herein are assays, kits and methods for treating mood disorders by testing for one or more polymorphisms in a specific group of genes and for analyzing the results of polymorphism testing; the genes included may converge in one or more signaling pathways, and may be epigenetic. The genes are included based on the relationships of the proteins encoded by the genes in the context of particular signaling pathways and provide a diagnostically relevant nexus. Also described herein are methods of presenting the data collected by the screen, including methods of delivering interpretive comments and/or treatment guidance based on the results of the genetic screening either individually or based on the genetic composition of particular clusters of genes which may be related to each other. Importantly, drugs which modulate these genetic disturbances are described for targeted therapeutic use based upon companion diagnostic method. | 2014-10-30 |
20140323425 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF A VIRAL INFECTION, AND METHOD FOR EVALUATING THE SENSITIVITY TO SAID TREATMENT - The present invention describes the use of nucleoside analogues for the treatment of viral infections, in particular of an HIV infection, and also compositions comprising at least one of these analogues, and a method for evaluating the sensitivity to said treatment. | 2014-10-30 |